Skip to main content
Premium Trial:

Request an Annual Quote

Pronota CEO Resigns as Firm Raises $4.9M

NEW YORK (GenomeWeb News) – Belgian protein diagnostic firm Pronota recently announced the closing of a Series C financing round that raised €3.7 million ($4.9 million).

The company also announced Nick McCooke has resigned as its CEO and as a board member.

The financing will go toward the completion of protein biomarker studies in support of the company's programs for the development of preeclampsia, ovarian cancer, sepsis, and cardio-renal products. Participants in the round included existing investors LSP; Gimv; Biotech Fund Flanders; KBC Private Equity; Johnson & Johnson Development; VIB; MP Healthcare, MedSciences Capital; and a company founder.

Pronota raised €7.9 million in a Series B round in 2010.

The company also said that McCooke has left the company after six years as CEO in order to pursue opportunities closer to his UK home base. Prior to joining Pronota, McCooke had been the CEO of Solexa.

He is being replaced by Katleen Verleysen, who had been Pronota's COO.

Also, John Berriman is stepping down as chairman of the board and being replaced by Rudy Dekeyser, managing director at VIB, Pronota said.

The company uses mass spectrometry-based technologies for the discovery and validation of biomarkers for diagnostic purposes.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.